An observational study in Giant Cell Arteritis (GCA), Aortic Dilatation and Aortic Aneurysm, sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to find out whether ultrasound can reliably detect dilatation and aneurysms of the aorta, the main blood vessel that carries blood from the heart to the rest of the body, in people with giant cell arteritis (GCA). GCA causes inflammation in the blood vessel walls. It can affect the aorta and increase the risk of aortic dilatation and aneurysms. Aortic dilatation is an abnormal widening of the aorta. When it becomes large, it is called an aneurysm, and can lead to serious complications.
The main questions the study aims to answer are:
How accurately can ultrasound performed by rheumatologists detect dilatation and aneurysms of the aorta compared with computed tomography (CT) angiography, which provides detailed images of the aorta?
How consistently do different rheumatologists evaluate the aorta using ultrasound?
How often is aortic dilatation and aneurysms found in people with GCA who previously had signs of inflammation in the aorta on a PET-CT scan?
Researchers will compare ultrasound measurements with CT angiography findings to assess how well ultrasound detects aortic dilatation and aneurysms.
The study will include 102 participants: 82 people with GCA and previous signs of aortic inflammation on PET-CT, 10 people with GCA and a known aortic dilatation or aneurysm, and 10 people with aortic dilatation or aneurysm not caused by inflammation.
Participants will undergo an ultrasound examination of the ascending aorta, the part of the aorta closest to the heart. Participants will also undergo CT angiography of the aorta, which uses X-rays and contrast dye to produce detailed images of the blood vessel. The ultrasound measurements will be compared with the CT angiography findings. The ultrasound evaluations of the ultrasound performing rheumatologists will be compared with evaluations of a blinded assessor.
The long-term aim is to determine whether ultrasound could be a useful, non-invasive screening method to help identify aortic dilatation and aneurysms in people with GCA.
149 studies on the registry are indexed under Giant Cell Arteritis; 49 are open to participants now.
This study's planned enrollment of 102 is below the median of 122 across 79 observational studies indexed under Giant Cell Arteritis.
Browse Giant Cell Arteritis studies →Esbjerg Hospital - University Hospital of Southern Denmark is the lead sponsor of 51 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
GCA patients will be recruited from the five Rheumatology clinics of the Region of Southern Denmark (Odense University Hospital, Svendborg Hospital, Esbjerg Hospital, the Danish Hospital for Rheumatic Diseases, Lillebælt Hospital). Non-GCA patients will be recruited from the Cardiology clinic of Esbjerg Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Specifically for the "GCA without known dilatation or aneurysm of the aorta" cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GCA patients with involvement of the thoracic aorta in the initial PET-CT upon diagnosis who have or have had regular follow-ups in the Rheumatology Clinics of the Region of Southern Denmark, who do not have known aortic dilatation or aneurysm, will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta and CT angiography of the aorta. Inclusion will stop at 82 subjects.
GCA patients with CT or MR angiography-established dilatation or aneurysm of the thoracic aorta who have or have had regular follow-ups in the Rheumatology clinics of the Region of Southern Denmark will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects
Patients with CT or MR angiography established dilatation or aneurysm of the thoracic aorta on a non-inflammatory basis who have regular follow-ups in the Cardiology Clinic in Esbjerg Hospital will be invited to the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects.
Diagnostic accuracy of thoracic aorta ultrasound for detecting aortic dilatation and aneurysms
The ability of ultrasound measurements of the thoracic aorta to identify aortic dilatation or aneurysms will be evaluated using CT angiography as the reference standard. A receiver operating characteristic (ROC) curve will be used to assess how well the ultrasound measurements distinguish between participants with and without aortic dilatation or aneurysms. Diagnostic performance will be summarized by calculating the area under the ROC curve (AUC).
Time frame: At the baseline study visit.
Agreement between assessors in ultrasound measurements of the thoracic aorta
Agreement between rheumatologists performing ultrasound examinations and an independent, blinded assessor will be evaluated by comparing their measurements of the thoracic aorta. Agreement will be quantified using the intraclass correlation coefficient (ICC), which indicates how closely the measurements agree. A two-way random-effects model assessing absolute agreement will be used (ICC\[2,1\]).
Time frame: At the baseline study visit.
Prevalence of thoracic aortic dilatation and aneurysm in GCA patients with prior FDG-PET/CT-confirmed aortic uptake
The prevalence of thoracic aortic dilatation and aneurysm will be assessed among the patients with giant cell arteritis (GCA) and aortic FDG uptake on PET/CT at diagnosis. Thoracic aortic diameters will be measured with CT angiography and aortic dilatation and aneurysm will be classified according to prespecified diameter-based diagnostic criteria. Prevalence will be calculated as the number of participants meeting the criteria for aortic dilatation or aneurysm at the study assessment divided by the total number of this cohort's participants with evaluable CT angiography scans. Aortic dilatation and aneurysm will also be reported separately, where applicable.
Time frame: At the baseline study visit.
No study locations are listed for this record.
Start is estimated for May 2027; primary completion for Dec 2029, 31 months later.
Of 45 observational studies under Giant Cell Arteritis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esbjerg Hospital - University Hospital of Southern Denmark